253 related articles for article (PubMed ID: 8672729)
21. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic effect of beta 2-microglobulin in multiple myeloma].
Ortega F; González M; Moro MJ; Gascón A; Duarte I; Martín M; Hernández J; Jiménez-Galindo R; Portero JA; Sanz M
Med Clin (Barc); 1992 Nov; 99(17):645-8. PubMed ID: 1447935
[TBL] [Abstract][Full Text] [Related]
23. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors and relative risk for survival in N1-3 oral squamous cell carcinoma: a multivariate analysis using Cox's hazard model.
Noguchi M; Kido Y; Kubota H; Kinjo H; Kohama G
Br J Oral Maxillofac Surg; 1999 Dec; 37(6):433-7. PubMed ID: 10687900
[TBL] [Abstract][Full Text] [Related]
25. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
26. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
[TBL] [Abstract][Full Text] [Related]
27. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome.
Acharya SK; Dasarathy S; Kumer TL; Sushma S; Prasanna KS; Tandon A; Sreenivas V; Nijhawan S; Panda SK; Nanda SK; Irshad M; Joshi YK; Duttagupta S; Tandon RK; Tandon BN
Hepatology; 1996 Jun; 23(6):1448-55. PubMed ID: 8675163
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of prognostic factors of and to establish a predictive model for patients with chronic severe hepatitis].
Zhang N; Wang YM; Deng GH; Yi D
Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):730-3. PubMed ID: 16248942
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of a morphologic staging method (myeloma progression score) in multiple myeloma].
Pasqualetti P; Casale R; Collacciani A; Colantonio D
Medicina (Firenze); 1989; 9(3):280-2. PubMed ID: 2615598
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma.
Reibnegger G; Krainer M; Herold M; Ludwig H; Wachter H; Huber H
Cancer Res; 1991 Dec; 51(23 Pt 1):6250-3. PubMed ID: 1933885
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors and therapeutic results in multiple myeloma.
Nagai M; Kitahara T; Minato K; Takenaka T; Konda C; Seki S; Shimoyama M
Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
[TBL] [Abstract][Full Text] [Related]
33. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma.
Kim JE; Yoo C; Lee DH; Kim SW; Lee JS; Suh C
Ann Hematol; 2010 Apr; 89(4):391-7. PubMed ID: 19844712
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
35. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
37. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
38. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
39. [BUN, Bence Jones protein, and chromosomal aberrations predict survival in multiple myeloma].
Okada K; Oguchi N; Shinohara K; Tamura N; Ishii K; Noguchi Y; Hayashi S; Yamamoto H; Takeichi M; Fujimoto H; Shirota T; Hayashi T
Rinsho Ketsueki; 1997 Dec; 38(12):1254-62. PubMed ID: 9455144
[TBL] [Abstract][Full Text] [Related]
40. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
